Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE: Neoadjuvant Nivolumab +/- Ipilimumab in CSCC
NCT04620200Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2020
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Netherlands Cancer Institute. Started Aug 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04620200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620200.